Dimension Therapeutics

Acquired by Ultragenyx Pharmaceuticals
AAV gene therapy developer for rare diseases.
AAV gene therapy developer for rare diseases.

F-Prime Team

Sector

Life Sciences

Category

Therapeutics

Location

Cambridge, MA

Initial Investment

2013
Dimension Therapeutics

Dimension Therapeutics was a leader in the development of AAV (adeno-associated virus) gene therapies for rare disease. Dimension Therapeutics was acquired by Ultragenyx Pharmaceuticals (NASDAQ: RARE).